Related Experiment Video
Updated: Jan 7, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
The Effectiveness of Low-dose 161 Tb-PSMA Treatment for Metastatic Castration-resistant Prostate Cancer
Fucen Liu1,2, Xia Yang2,3,4, Liming Xiao1,2
1Department of Nuclear Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Clinical Nuclear Medicine
|December 9, 2025
Summary
Low-dose 161-Terbium-PSMA radioligand therapy (RLT) showed promising results in a patient with metastatic castration-resistant prostate cancer. The treatment led to decreased PSA levels, reduced lesion uptake, and symptom relief without adverse effects.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) presents a significant therapeutic challenge.
- Patients often experience disease progression despite conventional treatments like antiandrogen therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose 161-Terbium-PSMA radioligand therapy (RLT) in a patient with mCRPC.
- To assess the impact of RLT on prostate-specific antigen (PSA) levels, metastatic lesion activity, and patient symptoms.
Main Methods:
- A 60-year-old male patient with mCRPC received two cycles of low-dose 161-Terbium-PSMA RLT (0.96 GBq and 1.11 GBq).
- Treatment response was monitored via PSA levels and 68-Gallium-PSMA PET/CT imaging.
- Clinical symptoms, including urinary retention, were assessed.
Main Results:
- A decrease in PSA levels was observed post-treatment.
- Reduced uptake in metastatic lesions on 68-Gallium-PSMA PET/CT indicated treatment effectiveness.
- Improvement in symptoms of urinary retention was reported.
- No acute toxicity or adverse reactions were documented.
Conclusions:
- Low-dose 161-Terbium-PSMA RLT demonstrated a positive therapeutic effect in this mCRPC patient.
- The treatment was well-tolerated, with no observed adverse events.
- RLT represents a potential treatment option for advanced prostate cancer.
